Expect a sharp negative stock reaction on the open. Monitor for analyst downgrades and any updates on the BEACON study. The continued BEACON program provides a small offset, but the idiopathic PD market was the primary opportunity.
DNLI drugs
DNLI drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $18.64entry
- T+1 · 6mo ago +3.97%α +3.38% · $19.38
- T+5 · 6mo ago +9.50%α +7.84% · $20.41
- T+20 · 5mo ago +30.77%α +32.18% · $24.38
- T+60 · 3mo ago +30.42%α +27.23% · $24.31
Price Chart
How similar events traded
Executive Summary
Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 in idiopathic Parkinson's disease will be discontinued, while the Phase 2a BEACON study in LRRK2 variant carriers continues. This is a significant pipeline setback for Denali.
Key Facts
- Phase 2b LUMA study (n=648) did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
- Secondary endpoints also showed no benefit for BIIB122 versus placebo.
- Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
- Denali will continue the Phase 2a BEACON study in LRRK2 pathogenic variant carriers, with data expected in first half of 2027.
- Exploratory biomarkers showed >90% peripheral LRRK2 kinase inhibition and up to ~30% reduction in CSF pRab10.
Financial Impact
Significant devaluation of the Parkinson's disease pipeline; BIIB122 was a key partnered asset with Biogen. The discontinuation removes a major value driver for Denali.
Risk Factors
- The BEACON study may also fail, eliminating the entire LRRK2 program.
- Partnership with Biogen may be reevaluated, impacting future collaboration revenues.
- Potential need for additional capital if pipeline value erodes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299824 |
Track record
17 reports on DNLI
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers